Galmed Pharmaceuticals (GLMD) Net Margin (2016 - 2018)

Galmed Pharmaceuticals' Net Margin history runs 3 years deep, the most recent figure standing at 53.93% for Q3 2018.

• In Q3 2018, Net Margin fell 97207.0% year-over-year to 53.93%; the TTM figure through Jun 2019 stood at 514.29% (down 56792.0% YoY), while the FY2018 annual figure was 476.25%, down 65730.0% from the prior year.
• Net Margin was 53.93% for Q3 2018 at Galmed Pharmaceuticals, down from 994.44% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 1876.68% in Q3 2016 to a low of 53.93% in Q3 2018.
• Historically, Net Margin has averaged 1141.1% across 3 years, with a median of 1026.01% in 2017.
• Biggest YoY gain for Net Margin was 259 bps in 2018; the steepest drop was 97207 bps in 2018.
• A 3-year view of Net Margin shows it stood at 1761.31% in 2016, then dropped by 24 bps to 1329.93% in 2017, then plunged by 96 bps to 53.93% in 2018.
• The last three Net Margin figures came in at 53.93% (Q3 2018), 994.44% (Q2 2018), and 974.63% (Q1 2018), per Business Quant data.